Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

In a world where alcohol claims nearly 178,000 lives annually in the U.S. alone, a glimmer of hope has emerged from an ...

Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their ...